Marinus Pharmaceuticals (MRNS) to Release Earnings on Wednesday

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) is scheduled to be releasing its earnings data before the market opens on Wednesday, May 8th. Analysts expect Marinus Pharmaceuticals to post earnings of ($0.68) per share for the quarter.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last posted its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. During the same period last year, the company posted ($0.76) EPS. On average, analysts expect Marinus Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Marinus Pharmaceuticals Trading Down 1.4 %

MRNS traded down $0.02 during trading on Thursday, hitting $1.45. 979,769 shares of the company's stock were exchanged, compared to its average volume of 1,458,047. The stock has a 50 day moving average price of $6.85 and a 200 day moving average price of $7.98. Marinus Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $11.26. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. The firm has a market cap of $79.65 million, a P/E ratio of -0.55 and a beta of 1.15.

Wall Street Analysts Forecast Growth

MRNS has been the subject of several recent research reports. Royal Bank of Canada reiterated a "sector perform" rating and issued a $3.00 price target (down from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. StockNews.com cut Marinus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, March 6th. Robert W. Baird reiterated a "neutral" rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. Cantor Fitzgerald reissued an "overweight" rating and set a $28.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, April 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $16.07.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.